ClinicalTrials.gg
RecruitingNCT07860827TRRATUpdated Oct 6, 2026

Efficacy of Robotic Upper Limb Rehabilitation Training in Patients With Tetraplegia

An interventional study of Robotic Rehabilitation with PABLO® and Standard Gym Rehabilitation in Tetraplegia/Tetraparesis, Rehabilitation Treatment and Gaining Skeletal Muscle Mass and Strength, sponsored by IRCCS Sacro Cuore Don Calabria di Negrar. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by IRCCS Sacro Cuore Don Calabria di Negrar · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Apr 2024, registered Sep 2026).
  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the efficacy of upper-limb robotic rehabilitation training (PABLO®) for recovering muscle strength in the scapulohumeral region and the proximal upper limb-compared to standard rehabilitation treatment alone-in male and female patients aged 18 to 80 years with tetraplegia/tetraparesis due to spinal cord injury of various etiologies (traumatic, ischemic, infectious, etc.) in the subacute phase.

Read the detailed description

The rehabilitation protocol includes:

- 2 weeks of standard upper limb gym rehabilitation treatment;

Randomization of patients into two treatment groups (lasting 3 weeks):

  • Arm A, undergoing upper-limb treatment solely with a robotic device;
  • Arm B, undergoing only standard physiotherapy treatment

For the evaluation of neurological assessment of motor and sensory functions will be used the American Spinal Injury Association (ASIA) Impairment Scale.

Specifically, the assessment of muscle strength of proximal muscles of the upper limb and the scapulohumeral region will be used the Medical Research Council (MRC) scale.

The enrollment evaluation (V0) consists of a physiatric examination, including an assessment of motor function and muscle strength in the scapulohumeral region and the proximal portions of the upper limbs, as well as any sensory deficits in the upper limbs, followed by determination of the neurological level of injury and classification according to the ASIA Impairment Scale. After two to four weeks of hospitalization, during which the patient undergoes standard rehabilitation, the examiner reevaluates the patient (V1).

After two weeks of standard upper-limb rehabilitation, the patient undergoes a further clinical reevaluation (V2) and is subsequently randomized into two treatment groups: Arm A (experimental arm) or Arm B (standard control arm). At the end of this training period, the patient will be re-evaluated (V3) by the same examiner who conducted the V1 visit and who will be blinded to the rehabilitation treatment received by the patient (the patient will be asked not to disclose the type of rehabilitation performed).

02

Conditions studied

  • Tetraplegia/Tetraparesis
  • Rehabilitation Treatment
  • Gaining Skeletal Muscle Mass and Strength

Browse trials for

Keywords

  • tetraplegia/tetraparesis
  • rehabilitation training
  • PABLO®
03

In context

Quadriplegia

224 studies on the registry are indexed under Quadriplegia; 77 are open to participants now.

This study's planned enrollment of 24 is above the median of 15 across 195 interventional studies indexed under Quadriplegia.

Browse Quadriplegia studies →

Lead sponsor

IRCCS Sacro Cuore Don Calabria di Negrar is the lead sponsor of 38 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. PRIMARY

    • The investigator obtains the patient's to participate in the clinical trial and to the processing of personal data.
    • Tetraplegic/tetraparetic patients with spinal cord injury of various etiologies (traumatic, ischemic, infectious, etc.) as defined by the ASIA Impairment Scale, who are capable of movements at least against gravity-even with a partial range of motion (MRC ≥2/5)-in the muscles of the scapulohumeral region and the elbow on at least one side of the body.
    • Age ≥ 18 years and ≤ 80 years.
    • Time interval between the acute event and study enrollment not exceeding 120 days.
  2. SECONDARY

    • Ability to maintain a seated position in a non-reclined wheelchair (trunk-pelvis angle of 90°) for one hour.
    • Improvement in strength of ≥ 1 point (out of 5) on the MRC scale in less than half of the upper limb regions assessed at Visit V1.

Exclusion criteria

Exclusion Criteria:

  • ASIA with a neurological level of C2 or higher.
  • Previous cerebrovascular events, neurodegenerative disorders, or spinal cord injuries that have resulted in motor and/or cognitive impairment.
  • History of major psychiatric disorders.
  • Concurrent traumatic brain injury during the acute phase.
  • Previous orthopedic conditions of the shoulder resulting in severe functional impairment.
  • Active rheumatological conditions.
  • Severe uncorrected visual impairment (such that it prevents the patient from viewing the computer-based exercises proposed by the robot).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Robotic Rehabilitation with PABLO®

    Device: Robotic Rehabilitation with PABLO®

  • Active comparator
    Standard Rehabilitation

    Procedure: Standard Gym Rehabilitation

Interventions

  • DeviceRobotic Rehabilitation with PABLO®

    3 weeks of robotic rehabilitation treatment with PABLO®, consisting of 15 rehabilitation sessions, each lasting 1 hour, for the upper limbs, focused on restoring strength and motor function. Treatments involve one-dimensional (lateral-lateral or anteroposterior) and two-dimensional active mobilization of the upper extremities using the PABLO® Multiboard, a device that secures the hand and wrist with a handle and allows for flexion and extension movements of the elbow and shoulder.

  • ProcedureStandard Gym Rehabilitation

    3 weeks of standard rehabilitation treatment, consisting of 15 rehabilitation sessions in the gym (5 per week for 3 consecutive weeks), each lasting 1 hour. Treatments are designed to maintain or restore range of motion in the shoulder joint through passive, active-assisted, and active mobilization exercises guided by the physical therapist, strength training of the proximal muscles of the upper limb, electrostimulation of the proximal muscles of the upper limb and use of physical therapies for analgesic and anti-inflammatory purposes.

06

What researchers measure

Primary outcomes

  1. Neurological assessment of motor function and sensation

    Neurological assessment of motor function and sensation using the American Spinal Injury Association (ASIA) Impairment Scale. Assessment of muscle strength using the Medical Research Council (MRC) scale for the proximal muscles of the upper limb and the scapulohumeral region (flexion-extension, abduction/adduction, internal and external rotation of the shoulder, and flexion-extension of the elbow), administered both before and after treatment.

    Time frame: From enrollment (Visit 0) to Visit 3 (7-9 weeks after Visit 0)

Secondary outcomes

  1. Passive Range of Motion (pROM)

    Passive Range of Motion (pROM) at the scapulohumeral joint across various planes of motion (flexion-extension, abduction/adduction, internal and external rotation of the shoulder, and flexion-extension of the elbow), measured both pre- and post-treatment

    Time frame: From enrollment (Visit 0) to Visit 3 (7-9 weeks after Visit 0)

  2. Numerical Rating Scale (NRS)

    Numerical Rating Scale (NRS) for assessing shoulder pain, recorded at all visits, both pre- and post-treatment;

    Time frame: From Visit 1 (2-4 weeks after Visit 0) to Visit 3 (7-9 weeks after Visit 0)

  3. Spinal Cord Independence Measure (SCIM-III) scale

    Spinal Cord Independence Measure (SCIM-III) scale, measured both pre- and post-treatment

    Time frame: From enrollment (Visit 0) to Visit 3 (7-9 weeks after Visit 0)

  4. number of sessions required before beginning 2D exercises

    number of sessions required before beginning 2D exercises

    Time frame: At Visit 2 (4-6 weeks after Visit 0) and Visit 3 (7-9 after Visit 0)

  5. Wheelchair Skills Test Italian Version 4.3 Powered Mobility Devices (WST-I 4.3 PMD)

    Wheelchair Skills Test Italian Version 4.3 Powered Mobility Devices (WST-I 4.3 PMD), measured pre- and post-treatment

    Time frame: At Visit 2 (4-6 weeks after Visit 0) and Visit 3 (7-9 after Visit 0)

  6. Modified Physical Therapy Patient Satisfaction Questionnaire (PTPSQ-1 mod)

    Modified Physical Therapy Patient Satisfaction Questionnaire (PTPSQ-1 mod), completed during the final visit

    Time frame: At Visit 3 (7-9 weeks after Visit 0)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Oct 2027, 42 months after the start.

Of 77 non-industry interventional studies with no phase under Quadriplegia, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 309. This study's planned 42 months is below that.

Counting every sponsor, half of 97 studies reached it within 41 months; a quarter within 16 and three quarters within 309.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Oct 6, 2026
StartActual
Apr 1, 2024
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 31, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07860827
Lead sponsor
IRCCS Sacro Cuore Don Calabria di Negrar
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Apr 1, 2024
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Elvia Malo, Dr.ssa
Contact
ricerca.clinica@sacrocuore.it
+39 045.6014877

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion